Research Perspectives:

From rapalogs to anti-aging formula

Mikhail V. Blagosklonny _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:35492-35507. https://doi.org/10.18632/oncotarget.18033

Metrics: PDF 6308 views  |   HTML 18259 views  |   ?  


Mikhail V. Blagosklonny1

1 Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, USA

Correspondence to:

Mikhail V. Blagosklonny, email:



Keywords: lifespan, longevity, rejuvenation, health, diseases

Received: February 17, 2017 Accepted: April 30, 2017 Published: May 22, 2017


Inhibitors of mTOR, including clinically available rapalogs such as rapamycin (Sirolimus) and Everolimus, are gerosuppressants, which suppress cellular senescence. Rapamycin slows aging and extends life span in a variety of species from worm to mammals. Rapalogs can prevent age-related diseases, including cancer, atherosclerosis, obesity, neurodegeneration and retinopathy and potentially rejuvenate stem cells, immunity and metabolism. Here, I further suggest how rapamycin can be combined with metformin, inhibitors of angiotensin II signaling (Losartan, Lisinopril), statins (simvastatin, atorvastatin), propranolol, aspirin and a PDE5 inhibitor. Rational combinations of these drugs with physical exercise and an anti-aging diet (Koschei formula) can maximize their anti-aging effects and decrease side effects.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18033